LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 1 | N12 | 72 | hr | 2543 | 4349 | 5258 | 0.8270 | 0.6684 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 2 | N12 | 72 | hr | 2543 | 5192 | 5438 | 0.9547 | 0.9173 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 3 | N12 | 72 | hr | 2543 | 5474 | 5557 | 0.9850 | 0.9734 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 1 | N11 | 72 | hr | 2543 | 3909 | 5258 | 0.7433 | 0.5070 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 2 | N11 | 72 | hr | 2543 | 4676 | 5438 | 0.8599 | 0.7427 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 3 | N11 | 72 | hr | 2543 | 5057 | 5557 | 0.9100 | 0.8395 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 1 | N10 | 72 | hr | 2543 | 3442 | 5258 | 0.6545 | 0.3347 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 2 | N10 | 72 | hr | 2543 | 4183 | 5438 | 0.7692 | 0.5743 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 3 | N10 | 72 | hr | 2543 | 4621 | 5557 | 0.8315 | 0.6981 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 1 | N09 | 72 | hr | 2543 | 3236 | 5258 | 0.6153 | 0.2583 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 2 | N09 | 72 | hr | 2543 | 3672 | 5438 | 0.6752 | 0.3979 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 3 | N09 | 72 | hr | 2543 | 3786 | 5557 | 0.6813 | 0.4230 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 2543 | 2873 | 5258 | 0.5463 | 0.1233 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 2543 | 3529 | 5438 | 0.6489 | 0.3481 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 2543 | 3573 | 5557 | 0.6429 | 0.3518 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 1 | N07 | 72 | hr | 2543 | 2145 | 5258 | 0.4079 | -0.1501 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 2 | N07 | 72 | hr | 2543 | 2275 | 5438 | 0.4183 | -0.0967 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 3 | N07 | 72 | hr | 2543 | 2253 | 5557 | 0.4054 | -0.1020 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 2543 | 6340 | 5734 | 1.1056 | 1.1787 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 2543 | 6421 | 5761 | 1.1145 | 1.1925 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 2543 | 5967 | 5760 | 1.0358 | 1.0605 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 2543 | 6520 | 5734 | 1.1370 | 1.2313 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 2543 | 6020 | 5761 | 1.0449 | 1.0758 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 3 | N17 | 72 | hr | 2543 | 6159 | 5760 | 1.0691 | 1.1166 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 1 | N16 | 72 | hr | 2543 | 6457 | 5734 | 1.1260 | 1.2129 |